Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance. - Wikidata - wikimedia - TriplyDB

Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance.

Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance.

http://www.wikidata.org/entity/Q37446341

about

Simultaneously Targeting the NS3 Protease and Helicase Activities for More Effective Hepatitis C Virus Therapy Macrocyclic protease inhibitors with reduced peptide character Structural and Thermodynamic Effects of Macrocyclization in HCV NS3/4A Inhibitor MK-5172 Structural analysis of asunaprevir resistance in HCV NS3/4A protease Improving Viral Protease Inhibitors to Counter Drug Resistance.Improving the Resistance Profile of Hepatitis C NS3/4A Inhibitors: Dynamic Substrate Envelope Guided Design Novel therapeutic approaches for hepatitis C.Advances in newly developing therapy for chronic hepatitis C virus infection.Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease.Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants.Prediction of substrate specificity in NS3/4A serine protease by biased sequence search threading.

P2860

Q26700073-48100A9E-DED3-4349-AE53-F2469613B9A6 Q27690658-8F29BA25-9874-4D55-8880-E2004EA9884F Q27703170-D997B770-89BB-4AA7-8BBE-9FEBF52B4250 Q34576194-DB9C2A18-B6D7-474B-AF60-BFF8CE761D69 Q37017282-94F93D07-B4A8-4235-B055-A128C395DD3F Q37604079-904A3B5E-04B3-4097-9F43-4F9EF74105FB Q38152674-8F0564F6-EFAF-420C-A8C6-52763B0CAF09 Q38215652-B8440A60-72B0-4980-9AE9-3A319CAA2F4A Q39500905-B4725AF7-8467-47E8-8F06-E2F18BC3AB3C Q40167650-DC20DA8F-67D2-4ED8-AD64-4E14A70F0ACF Q40778605-D1DAC897-A41A-4163-8C5C-A7978554F648

P2860

Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance.

http://www.wikidata.org/entity/Q37446341

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Evaluating the role of macrocy ...... inhibitors to drug resistance.

@en

Evaluating the role of macrocy ...... inhibitors to drug resistance.

@nl

type

label

Evaluating the role of macrocy ...... inhibitors to drug resistance.

@en

Evaluating the role of macrocy ...... inhibitors to drug resistance.

@nl

prefLabel

Evaluating the role of macrocy ...... inhibitors to drug resistance.

@en

Evaluating the role of macrocy ...... inhibitors to drug resistance.

@nl

P1433

Q37446341-5846E352-683F-4EB8-8E2C-F89698E5FDBA

P1476

Q37446341-E7C5977B-4AB5-49AA-BF99-00EC2539F9BB

P2093

Q37446341-09BADEB9-A39F-4EF3-AB3A-33CCBC94621F

Q37446341-1B8D287B-8F79-483F-B7D7-C6A24A80F08E

Q37446341-392FF7BA-4827-4559-947B-0E3443195D5F

Q37446341-545715BB-60AA-474C-879C-61A56B609CF1

Q37446341-6CC91840-755C-4962-AE86-788ED72E5B1D

Q37446341-8B1841FD-78AA-487E-A174-1AD43AAAF36E

Q37446341-902FA029-8E6F-4E19-BB37-292B3F6A5A0D

Q37446341-B8E6EBEC-0772-4D1E-BE89-DEB9C81B07EB

Q37446341-F56D2105-BD9A-4664-B1E7-499DEEA7C741

P2860

Q37446341-011CF9A3-09EF-428F-B77D-992EC0409A76

Q37446341-057A727A-BCED-4362-9F8A-F53A585BC5B2

Q37446341-0A3B335F-8A20-462B-B5A2-A272B4E4FD97

Q37446341-0DE7707A-B243-4594-AF47-B7B43B4CA198

Q37446341-15DB29ED-6E5B-40BA-94DE-4782510C346A

Q37446341-186559F4-19BB-4D5A-AEF0-BB636F0617A3

Q37446341-1A4EB676-C71A-481A-A82F-6394D83CFD11

Q37446341-24F88823-A343-4382-B771-23E132FD1288

Q37446341-2A5E1A9F-6A3D-491F-80CC-84DC97EAA5D2

Q37446341-2C9F292A-48F6-4128-904F-46A411E72DBA

P304

Q37446341-9613BE2C-A3FB-4857-B753-BFABD24912FB

P31

Q37446341-2F638DCC-2282-4E33-8794-7A6E35F5FEF6

P356

Q37446341-9DA6E45D-E9B7-40AC-BAFC-A997695AB393

P433

Q37446341-5CC51F69-E3A9-4105-AFD4-059D0C67A642

P478

Q37446341-D47B3150-A561-4E17-91CA-89AB7F6F83C8

P50

Q37446341-8B9AFFC9-A1EE-4B3D-9031-7265DDD316DF

Q37446341-DA4E831F-B404-4EB0-A394-1489F2651B19

P577

Q37446341-D7C0D1D2-B169-417A-8ADD-1EBE30CDC0A6

P5875

Q37446341-839F40CD-5C77-4C58-B697-301A902C4AAC

P698

Q37446341-9D99CA61-A69A-415A-9869-2F383430C7E4

P932

Q37446341-AFE53A15-B2B6-45F0-9725-A01AED8449EA

P356

P1433

ACS Chemical Biology

P1476

Evaluating the role of macrocy ...... inhibitors to drug resistance

@en

P2093

Akbar Ali

http://www.w3.org/2001/XMLSchema#string

Alicia Newton

http://www.w3.org/2001/XMLSchema#string

Celia A Schiffer

http://www.w3.org/2001/XMLSchema#string

Christos J Petropoulos

http://www.w3.org/2001/XMLSchema#string

Djade Soumana

http://www.w3.org/2001/XMLSchema#string

Hong Cao

http://www.w3.org/2001/XMLSchema#string

Keith P Romano

http://www.w3.org/2001/XMLSchema#string

Reinhold Gildemeister

http://www.w3.org/2001/XMLSchema#string

Wei Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Boceprevir for previously treated chronic HCV genotype 1 infection

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor

GB virus B disrupts RIG-I signaling by NS3/4A-mediated cleavage of the adaptor protein MAVS

Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo

Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease

SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells.

Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)

MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease

Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding

P304

1469-1478

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/CB400100G

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236223417

http://www.w3.org/2001/XMLSchema#string

P698

23594083

http://www.w3.org/2001/XMLSchema#string

P932

3884027

http://www.w3.org/2001/XMLSchema#string